Amgen's anemia drug, the best-selling product developed so far by the biotechnology industry, might have broad new uses, recent studies have found. Laboratory and animal studies have shown that in addition to bolstering the body's red blood cells, the drug, EPO, is present in the central nervous system and acts to protect cells and tissues from damage and death. That could make it useful as a treatment for strokes, spinal cord injuries, multiple sclerosis and many other ailments. Testing in humans is in very early stages. A small study by academic scientists in Germany found that EPO, when given within...